NCT03312023 - Ledipasvir/Sofosbuvir for Hepatitis B Virus Infection | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 1, 2018

Primary Completion Date

August 10, 2020

Study Completion Date

June 30, 2021

Conditions

Hepatitis B

Interventions

DRUG

Ledipasvir 90 MG / Sofosbuvir 400 MG Oral Tablet [Harvoni]

1 pill once daily for 12 weeks for Group A

DRUG

Sofosbuvir 400 MG [Sovaldi]

1 pill once daily for 12 weeks for Group C

DRUG

Ledipasvir 90 MG

1 pill once daily for 12 weeks for Group D

Trial Locations (1)

Institute of Human Virology (IHV), University of Maryland Baltimore, Baltimore